Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.

TitleEvaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.
Publication TypeJournal Article
Year of Publication2012
AuthorsLi JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR
Corporate AuthorsAIDS Clinical Trials Group A5197 Study Team
JournalJ Acquir Immune Defic Syndr
Volume61
Issue1
Pagination19-22
Date Published2012 Sep 1
ISSN1944-7884
KeywordsAIDS Vaccines, gag Gene Products, Human Immunodeficiency Virus, Genetic Variation, HIV Infections, HIV-1, Humans, Immunotherapy, Molecular Sequence Data, Placebos, pol Gene Products, Human Immunodeficiency Virus, Sequence Analysis, DNA, Withholding Treatment
Abstract

Nucleotide mixtures in human immunodeficiency virus type 1 (HIV-1) population sequences reflect sequence diversity. We evaluated gag and pol ambiguous nucleotide frequencies during an analytic treatment interruption (ATI) in an HIV-1 therapeutic vaccine study. The proportion of ambiguous nucleotides was significantly higher at ATI week 16 than at either the time of first detectable viremia (P < 0.001 gag and P = 0.03 reverse transcriptase) or preantiretroviral therapy (P = 0.007 gag). No significant differences were observed in the proportion of ambiguous nucleotides between those receiving vaccine and placebo. Increased HIV diversity during the ATI may represent a potentially higher barrier to success for a therapeutic as compared with a preventative vaccine targeting cell-mediated immunity.

DOI10.1097/QAI.0b013e318264460f
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID22732468
PubMed Central IDPMC3427424
Grant ListK24 RR016482 / RR / NCRR NIH HHS / United States
K24 RR016482 / RR / NCRR NIH HHS / United States
P30 AI060354 / AI / NIAID NIH HHS / United States
P30 AI60354 / AI / NIAID NIH HHS / United States
T32 AI007387 / AI / NIAID NIH HHS / United States
T32 AI07387 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States